These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9527462)

  • 1. [Patient education responsibility, specialty and administration information from the viewpoint of the pharmaceutical industry].
    Granitza A
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):649-53. PubMed ID: 9527462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Education responsibility, specialty and administration information from the legal viewpoint].
    Schreiber HL
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):653-7. PubMed ID: 9527463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Patient education responsibility, specialty and administration information from the internal medicine viewpoint].
    Ludwig WD
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):657-61. PubMed ID: 9527464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Approval of drugs by national and European agencies--sequelae for the pharmaceutical industry].
    Zierenberg O
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):596-600. PubMed ID: 9527448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
    Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
    Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Modification of the prescribing practice of the physician by decisions of drug committees, specialty groups and consensus conferences].
    Müller-Oerlinghausen B
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):606-10. PubMed ID: 9527451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
    Shani S; Yahalom Z
    Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
    [No Abstract]   [Full Text] [Related]  

  • 10. [Modification of the prescribing practice of the physician by legislation with special reference to non-approved drugs].
    Bergmann KO
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):610-6. PubMed ID: 9527452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Responsibility for patient education in drug therapy from the viewpoint of the pharmaceutical industry].
    Sander A
    Z Arztl Fortbild (Jena); 1994 Dec; 88(12):1061-3. PubMed ID: 7716983
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug advertising--users want information. Report of telephone survey conducted by North-Rhine Westphalia Public Health Service on the topic of drug advertising and drug information for users].
    Puteanus U
    Gesundheitswesen; 2000 Oct; 62(10):516-24. PubMed ID: 11103563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Responsibility for patient education in drug therapy from the viewpoint of the drug industry].
    Lerch C
    Z Arztl Fortbild (Jena); 1994 Dec; 88(12):1055-60. PubMed ID: 7716982
    [No Abstract]   [Full Text] [Related]  

  • 15. [Autonomy attitudes in the treatment compliance of a cohort of subjects with continuous psychotropic drug administration].
    Baumann M; Trincard M
    Encephale; 2002; 28(5 Pt 1):389-96. PubMed ID: 12386539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 17. The patient information and education initiative.
    Rheinstein PH; McGinnis TJ; Nightingale SL
    Am Fam Physician; 1995 Dec; 52(8):2377-8, 2381-2. PubMed ID: 7484726
    [No Abstract]   [Full Text] [Related]  

  • 18. Direct-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward.
    Kravitz RL; Bell RA
    Clin Pharmacol Ther; 2007 Oct; 82(4):360-2. PubMed ID: 17851573
    [No Abstract]   [Full Text] [Related]  

  • 19. Organisations question EC changes on drug information for patients.
    Watson R
    BMJ; 2009 Mar; 338():b894. PubMed ID: 19261668
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient information leaflets--helpful guidance or a source of confusion?
    Bjerrum L; Foged A
    Pharmacoepidemiol Drug Saf; 2003; 12(1):55-9. PubMed ID: 12616848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.